article Open AccessTop 1% cited

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

Cochrane Database of Systematic Reviews · 2012 · Vol. 2012(3) · pp. 191–206

Robert G. Miller✉(California Pacific Medical Center)John D. Mitchell(Royal Preston Hospital)Dan H. Moore(California Pacific Medical Center)

View via DOI Full-text PDF

Abstract

Riluzole 100 mg daily is reasonably safe and probably prolongs survival by about two months in patients with ALS. More studies are needed, especially to clarify its effect in older patients (over 75 years), and those with more advanced disease.

Amyotrophic Lateral Sclerosis Research Neurogenetic and Muscular Disorders ResearchRiluzoleAmyotrophic lateral sclerosisMedicinePlaceboAdverse effectClinical trialRandomized controlled trialInternal medicineAnesthesiaDisease

MeSH terms

AdultAmyotrophic Lateral SclerosisDouble-Blind MethodDrug EvaluationHumansMusclesQuality of LifeRiskTime FactorsMulticenter Studies as TopicSurvival AnalysisRandomized Controlled Trials as TopicMotor Neuron DiseaseTreatment OutcomeNeuroprotective Agents

Citations

1,043

FWCI

48.67

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Chronic Glutamate Toxicity in Neurodegenerative Diseases—What is the Evidence?